Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 12—December 2024
Dispatch

Mpox Vaccine Acceptance, Democratic Republic of the Congo

Skylar Petrichko1, Jason Kindrachuk1, Dalau Nkamba, Megan Halbrook, Sydney Merritt, Handdy Kalengi, Leonard Kamba, Michael Beya, Nicole A. Hoff, Christophe Luhata, Didine K. Kaba2, and Anne W. Rimoin2Comments to Author 
Author affiliation: Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles, California, USA (S. Petrichko, M. Halbrook, S. Merritt, N.A. Hoff, A.W. Rimoin); Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada (J. Kindrachuk); Kinshasa School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo (D. Nkamba, H. Kalengi, L. Kamba, M. Beya, D.K. Kaba); Ministry of Health, Kinshasa (C. Luhata)

Main Article

Figure 1

General mpox vaccine attitudes and perceptions from a telephone phone survey about mpox vaccine acceptance conducted during December 2023–February 2024, by province, Democratic Republic of the Congo. A) Reported responses to the statement: new vaccines carry more risks than older vaccines; B) reported responses to the statement: information I receive about vaccines from the vaccine program is reliable and trustworthy. Provinces are listed by whether they had confirmed, suspected, or no mpox cases detected. The 3-level responses were collapsed from a 5-point Likert scale.

Figure 1. General mpox vaccine attitudes and perceptions from a telephone phone survey about mpox vaccine acceptance conducted during December 2023–February 2024, by province, Democratic Republic of the Congo. A) Reported responses to the statement: new vaccines carry more risks than older vaccines; B) reported responses to the statement: information I receive about vaccines from the vaccine program is reliable and trustworthy. Provinces are listed by whether they had confirmed, suspected, or no mpox cases detected. The 3-level responses were collapsed from a 5-point Likert scale.

Main Article

1These first authors contributed equally to this article.

2These last authors contributed equally to this article.

Page created: October 15, 2024
Page updated: November 26, 2024
Page reviewed: November 26, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external